Peng Wei

A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma

J. Hou, X. Ke, L. Qiu, 2014, American journal of hematology.

Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer-weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study.

Jason B. White, K. Hwang, G. Rauch, 2021, Radiology. Imaging cancer.

A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma

J. Hou, L. Qiu, Wenming Chen, 2017, American journal of clinical oncology.

The novel glycyrrhetinic acid-tetramethylpyrazine conjugate TOGA induces anti-hepatocarcinogenesis by inhibiting the effects of tumor-associated macrophages on tumor cells.

Zihui Xu, Bing Xu, Haimin Lei, 2020, Pharmacological research.

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

Yan Liu, Hua Jiang, B. Jiang, 2017, Cancer Chemotherapy and Pharmacology.

Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma

J. Hou, X. Ke, L. Qiu, 2014 .

A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.

Jason B. White, J. Hazle, V. Valero, 2022, European journal of radiology.